The gene CHST9 impacts the pharmacokinetics of drugs by affecting their sulfate conjugation process, due to CHST9's role in sulfating carbohydrates. This impact could potentially alter a drug's availability or activity, thereby affecting its efficacy and safety, particularly in treatments involving the modulation of tumor environments in cancer therapies.